Wuxi AppTec joins biologics IPO rush

Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.

Wuxi AppTec joins biologics IPO rush

Chinese biopharmaceutical firm Wuxi AppTec has taken the first step to relist its assets in Asia, launching a HK$3.6 billion to HK$4 billion $461m to $511 million initial public offering for its biologics division in Hong Kong on Wednesday.

The Wuxi Biologics IPO comes 18 months after its parent was delisted from the New York stock exchange in December 2015. The parent, then known as Wuxi Pharma...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES